Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PeptiDream Inc.
RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
A new national project to support bioventures and the venture capital funds investing in them has started in Japan. The strategic aim of the JPY50bn initiative is to enhance the speed of development and trials of new drugs and vaccines for infectious diseases, the lack of which became obvious since the breakout of COVID-19.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Natural Products
- Molecular Diversity
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.